Nikolas Herold

The paper analyzes subclonal gene dosage effects in cancer using DNTR-seq, finding additive and compensatory transcriptional impacts and identifying transient clonality in ovarian and soft tissue sarcomas.

This paper introduces a functionalist oncology framework using edge-weighted digraphs to model AML treatment dynamics and evaluate drug combinations, including SAMHD1 inhibitors.

This study identifies UBA1 mis-splicing as a therapeutic target in SF3B1-mutant myelodysplastic syndromes, showing that UBA1 inhibition sensitizes these cells to treatment.